Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001067752 | SCV001232827 | uncertain significance | Ullrich congenital muscular dystrophy 2; Bethlem myopathy 2 | 2022-02-11 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. ClinVar contains an entry for this variant (Variation ID: 861265). This variant has not been reported in the literature in individuals affected with COL12A1-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 2784 of the COL12A1 protein (p.Pro2784Leu). |
Revvity Omics, |
RCV003145334 | SCV003831186 | uncertain significance | not provided | 2020-10-26 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004977987 | SCV005557958 | uncertain significance | Inborn genetic diseases | 2024-10-06 | criteria provided, single submitter | clinical testing | The c.8351C>T (p.P2784L) alteration is located in exon 56 (coding exon 55) of the COL12A1 gene. This alteration results from a C to T substitution at nucleotide position 8351, causing the proline (P) at amino acid position 2784 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |